Jenny Fong Wang

7868032, Jan 11, 2011

Oct 9, 2007

11/869697

David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Newport Coast CA, US
Clive L. Cornell - Saffron Walden, GB
Hans G. Fliri - Saffron Walden, GB
Jose L. Martos - Basildon, GB
Simon N. Pettit - Colchester, GB

Allergan, Inc. - Irvine CA

A61K 31/422
C07D 263/30
C07D 311/02

514374, 548236, 549398

The present invention provides prostamide receptor antagonist compounds that may be represented by the general formula I.

8492424, Jul 23, 2013

Jun 28, 2011

13/170467

William R. Carling - Bishop's Stortford, GB
Jose L. Martos - Basildon Essex, GB
David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Irvine CA, US
Jussi J. Kangasmetsa - Essex, GB

Allergan, Inc. - Irvine CA

A61K 31/415
C07D 231/10

514406, 5483761

The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula.

20100256385, Oct 7, 2010

Apr 1, 2010

12/752179

David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Newport Coast CA, US

ALLERGAN, INC. - Irvine CA

C07D 263/40

548236

The present invention provides prostaglandin receptor antagonist compounds represented by the general formula I,wherein A, R, Rand Rare as defined in the specification.

20100298436, Nov 25, 2010

May 19, 2010

12/782972

David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Newport Coast CA, US

ALLERGAN, INC. - Irvine CA

A61K 31/196
C07C 235/64
A61P 29/00
A61P 27/02

514563, 562455

An EP2-receptor agonist of the following structure is disclosed:which is useful in the treatment of pain, inflammation and lowering intraocular pressure.

20110201684, Aug 18, 2011

Apr 27, 2011

13/095372

David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Newport Coast CA, US

ALLERGAN, INC. - Irvine CA

A61K 31/195
C07C 229/34
A61P 27/02
A61P 27/06

514567, 562442

A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP-receptor agonist represented by

20120077857, Mar 29, 2012

Jun 28, 2011

13/171020

Jenny W. WANG - Newport Coast CA, US
David F. WOODWARD - Lake Forest CA, US
Ming NI - Laguna Niguel CA, US
Jose L. MARTOS - Basildon Essex, GB
William R. CARLING - Basildon Essex, GB

ALLERGAN, INC. - Irvine CA

A61K 31/422
A61P 17/06
A61P 9/10
A61P 17/00
A61P 13/12
A61P 11/00
A61P 37/08
A61P 11/06
A61P 1/00
A61P 15/00
A61P 27/02
A61P 3/04
A61P 3/10
A61P 1/16
A61P 25/28
A61P 25/00
A61P 29/00

514374

The present invention provides a method for treating inflammation in a patient in need thereof comprising administering to said patient an effective amount of a compound according to formulawherein R is H or lower alkyl, R1 is hydrocarbyl or substituted hydrocarbyl and the broken line represents a saturated or unsaturated bond, i.e a double bond. Preferably, R1 is an alkyl. More preferably, R1 is a n-alkyl or a cycloalkyl-n-alkyl, e.g. a cyclohexyl-n-alkyl, e.g. n-octyl, n-nonyl or cyclohexyl-n-butyl radical and prodrugs, isomers and pharmaceutically acceptable salts thereof.

20120077858, Mar 29, 2012

Aug 19, 2011

13/213686

Jose L. Martos - Basildon Essex, GB
William R. Carling - Bishop's Stortford, GB
David F. Woodward - Lake Forest CA, US
Jenny W. Wang - Newport Coast CA, US
Jussi J. Kangasmetsa - Saffrom Waldon, GB

ALLERGAN, INC. - Irvine CA

A61K 31/422
A61P 29/00
C07D 413/14
C07D 413/04

514374, 548236

The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula

20120190733, Jul 26, 2012

Jan 20, 2012

13/354479

Jenny W. Wang - Irvine CA, US
David F. Woodward - Lake Forest CA, US

A61K 31/216
A61P 17/14
A61K 31/343
A61K 31/192
A61K 31/381

514443, 514510, 514569, 514469

The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles or increasing one or more of: length, thickness, number, and density, of eyelash hair or eyebrow hair comprising applying to the skin of a patient a composition comprising an effective amount of an EPagonist or an EPagonist prodrug or a mixture thereof. Such compositions which are used in treating the skin or scalp of a human or non-human animal may comprise an effective amount of 3, 7 or 3 and 7 thia prostanoic acid. A mixture of 3,7-dithia PGE1 and 3,7-dithiaPGE1-isopropyl ester is preferred for this treatment.